Accelerated radiation treatment for breast cancer
Accelerated Super-Hypofractionated Breast Brachytherapy - ASHBY Trial
This study is testing a quicker way to give radiation treatment for breast cancer in patients who have just had surgery to see if it is safe and effective.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 170 (estimated) |
| Ages | 45 Years to 79 Years |
| Sex | Female |
| Sponsor | Virginia Commonwealth University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Richmond, Virginia) |
| Trial ID | NCT06185205 on ClinicalTrials.gov |
What this trial studies
This phase 2, single-arm prospective study aims to evaluate the safety of accelerated partial breast irradiation (APBI) using a multicatheter interstitial implant over a short course of 1.5 days. The study focuses on patients with a new diagnosis of ductal carcinoma in situ (DCIS) or invasive breast carcinoma who have undergone lumpectomy with clear surgical margins. By administering radiation in just three treatments, the study seeks to determine the balance of benefits and risks associated with this rapid approach to breast cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are females aged 45-79 with a new diagnosis of DCIS or invasive breast carcinoma who have had a lumpectomy with clear margins.
Not a fit: Patients with advanced breast cancer or those who do not meet the specific eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a more efficient and less burdensome radiation option for breast cancer patients.
How similar studies have performed: Other studies have explored accelerated radiation approaches, showing promising results, but this specific method is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female * New diagnosis of ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma per histologic evaluation * Age 45-79 at diagnosis * Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist. * T stage of Tis, T1, or T2. * T2 tumors must be ≤3 cm in maximum diameter * If the tumor is human epidermal growth factor receptor 2 (HER2)-positive, the patient must receive HER2-directed therapy. * For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy alone or axillary dissection \[with a minimum of 6 axillary nodes removed\]) and the axillary node\[s\] must be pathologically negative. * Note: N0(i+) is not an exclusion criterion. * Note: Patients meeting all of the following criteria are not required to undergo the axillary staging procedure: * ≥70 years of age * estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-) * G1-2 * Tumor ≤2 cm in size * Agrees to comply with aromatase inhibitor recommendation * Ability to understand and the willingness to sign a written informed consent document in English Exclusion Criteria: * Pregnant or breastfeeding * Active collagen-vascular disease * Paget's disease of the breast * History of DCIS or invasive breast cancer prior to the current diagnosis * Prior breast or thoracic radiation therapy (RT) for any condition * Multicentric carcinoma (DCIS or invasive) * Synchronous bilateral invasive or non-invasive breast cancer * Surgical margins that cannot be microscopically assessed or that are positive * Excision cavity that cannot be clearly delineated per the treating investigator * Any of the dosimetric treatment criteria defined in Section 6.1 have not been met. Patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as - defined in this protocol and will come off the study. Any subsequent adjuvant radiation will be delivered at the discretion of the treating physician * Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Where this trial is running
Richmond, Virginia
- Virginia Commonwealth University — Richmond, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: Bridget Quinn, MD, Ph.D — Virginia Commonwealth University
- Study coordinator: Massey IIT Research Operations
- Email: masseyepd@vcu.edu
- Phone: 804-628-6430
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.